Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in ...

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

In announcing (Chinese) ivonescimab’s Chinese approval in first-line PD-L1-positive non-small cell lung cancer on Friday, Akeso noted that the bispecific drug slashed the risk of death by 22.3% ...

HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 ...

Professor Park Joon-sik of obstetrics and gynecology at Soonchunhyang University Bucheon Hospital announced on the 14th that he proved the effect of improving the survival rate of advanced ovarian ...

Merus N.V. announced that an abstract for petosemtamab combined with pembrolizumab as a first-line treatment for PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC ...

NICE says these patients taking Opdivo who had more PD-L1 (levels of 10% or more) on their cancer cells lived up to seven months longer than those with less. The committee have asked Bristol ...

The PFS benefit was demonstrated in patients with either PD-L1-positive or PD-L1-negative tumors. Akeso noted that no new safety signals were identified in this Phase III study. The full data set ...

The most advanced molecules in its pipeline target the IC proteins cluster of differentiation 47 (CD47) and PD-L1, a ligand of programmed cell death 1 (PD-1) (Fig. 1). It is now well established ...

Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced ... ($412.3 million) by this figure, it implies a cash runway extending into ...

This could also occur for the PD-1 and PD-L1 immunotherapies in melanoma; similarly, a broad label in lung cancer could be limited to patients not suitable for ALK inhibitor therapies like Xalkori ...